Blys

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

BAFF; B-cell activating factor; B-cell activation factor

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

  • Acronym for "soluble human B lymphocyte stimulator protein". BLyS is a naturally occurring protein that is essential for the maturation, survival and function of B lymphocytes. BLyS belongs to the tumor necrosis factor superfamily (see below tumor necrosis factor-α) and is membrane-bound and dissolved in its active form. BLyS is expressed on cells of the innate immune system, on neutrophil granulocytes, monocytes and macrophages; furthermore on dendritic cells and some T- and B-cells.
  • 3 different receptors are currently detected on B cells: BLys receptor 1-3, with BLyS receptor 3 (BR3, syn. BAFFr) being the most important. The BLyS3 receptor performs a crucial function in antibody production by inhibition of selection and apoptosis of autoreactive B cells.
  • In SLE patients (see below lupus erythematosus, systemic) it has been shown that serum levels of BLyS are elevated and correlate with the concentration of double-stranded antibodies. It is assumed that in systemic lupus erythematosus and certain other autoimmune diseases, elevated BLyS levels contribute to the production of autoantibodies. Inhibition of BLyS by a monoclonal antibody ( Belimumab) led to an improvement in the clinical picture.

LiteratureThis section has been translated automatically.

  1. Dubey A K (2011) First targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother 2: 317-319
  2. Glasses N (2012) Belimumab dermatologist 63: 253-255
  3. Navarra SV (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377: 721-731

Authors

Last updated on: 29.10.2020